The Phosphatidylinositol 3-Kinase Pathway in Human Malignancies
© 2016 by John Wiley & Sons, Inc. All rights reserved.Cancer accounts for one-quarter of all deaths in the United States, and alterations in the phosphatidylinositol-3-kinase (PI3K) pathway components are some of the most frequent genomic alterations in human malignancies. The study of the PI3K pathway has translated into improved understanding of tumorigenesis and led to the identification of multiple therapeutic targets. Inhibition of the PI3K pathway across multiple tumor types is already translating into improved patient outcomes in several cancers, and multiple clinical investigations are ongoing. In this chapter, we have reviewed the major components of the canonical PI3K signal transduction cascade and highlighted translational studies investigating inhibition of the PI3K pathway in human malignancies.
Digital Object Identifier (DOI)
Additional Document Info